WEE1 and familial pancreatic carcinoma: Several of the discovered WEE1 inhibitors are of clinical grade and a few are in early-phase clinical development, although, currently, few trials have been specific for pancreatic cancer patients and no trials have used molecular markers of DNA damage for patient selection.